KRAS
-
New MD Anderson Research Uncovers Drug Combo That Could Eliminate Pancreatic Cancer Tumors
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
-
Trovagene tries roundabout approach to colorectal cancer with ‘undruggable’ mutation
Although they’re still early, the company presented Phase Ib/II study data showing its PLK1 inhibitor, onvasertib, was able to produce responses in KRAS-mutated metastatic CRC, through a property known as synthetic lethality. KRAS-specific drugs have shown low efficacy in mCRC.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Merck partners with Taiho, Otsuka in $2.5B bet on KRAS-targeting cancer drugs
The companies said Monday that they would partner to develop small-molecule oncology drugs against several targets, including KRAS mutations, long thought “undruggable.” Amgen and Mirati have already presented clinical data from their KRAS programs.
-
Mirati presents data on drug with tough-to-reach target, setting up competition with Amgen
An analyst noted that Mirati’s MRTX849, a KRAS G12C inhibitor, is six to nine months behind Amgen’s AMG 510, but that the market has room for both. The data presented were on patients with lung and colorectal cancers.
-
Amgen cancer drug with ‘undruggable’ target shows more progress
The company said in its earnings statement that AMG 510 had produced objective responses in patients with colorectal and appendiceal cancers. The Phase II portion of the Phase I/II study, which may be used for registration, will start enrolling in the coming days.
-
Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets
The company is targeting pathways such as SHP2 and KRAS G12C. RAS mutations have been an attractive target in oncology due to the central role they play in cancers.
-
Frontier Medicines launches with $67M Series A, hopes to go after ‘undruggable’ targets
Many proteins known to play roles in cancers are considered “undruggable” because they lack pockets for drugs to bind to. Amgen drew attention at ASCO with data on a drug targeting a KRAS mutation, generally considered not amenable to pharmaceutical therapy.